Skip to main content

Sepsis - what's in the discovery pipeline?

  1. Disruption of the endothelial glycocalyx (eGC) is observed in septic patients and its injury is associated with multiple-organ failure and inferior outcomes. Besides this biomarker function, increased blood co...

    Authors: Klaus Stahl, Uta Carola Hillebrand, Yulia Kiyan, Benjamin Seeliger, Julius J. Schmidt, Heiko Schenk, Thorben Pape, Bernhard M. W. Schmidt, Tobias Welte, Marius M. Hoeper, Agnes Sauer, Malgorzata Wygrecka, Christian Bode, Heiner Wedemeyer, Hermann Haller and Sascha David
    Citation: Intensive Care Medicine Experimental 2021 9:57
  2. The pathophysiology of sepsis is multi-facetted and highly complex. As sepsis is a leading cause of global mortality that still lacks targeted therapies, increased understanding of its pathogenesis is vital fo...

    Authors: Alex R. Schuurman, Tom D. Y. Reijnders, Robert F. J. Kullberg, Joe M. Butler, Tom van der Poll and W. Joost Wiersinga
    Citation: Intensive Care Medicine Experimental 2021 9:27
  3. Despite decades of preclinical research, no experimentally derived therapies for sepsis have been successfully adopted into routine clinical practice. Factors that contribute to this crisis of translation incl...

    Authors: Asher A. Mendelson, Casey Lansdell, Alison E. Fox-Robichaud, Patricia Liaw, Jaskirat Arora, Jean-Fran├žois Cailhier, Gediminas Cepinskas, Emmanuel Charbonney, Claudia dos Santos, Dhruva Dwivedi, Christopher G. Ellis, Dean Fergusson, Kirsten Fiest, Sean E. Gill, Kathryn Hendrick, Victoria T. Hunniford…
    Citation: Intensive Care Medicine Experimental 2021 9:14
  4. To expand upon the priorities of fluid resuscitation and vasopressor therapy research priorities identified by a group of experts assigned by the Society of Critical Care Medicine and the European Society of I...

    Authors: Ishaq Lat, Craig M. Coopersmith, Daniel De Backer and Craig M. Coopersmith
    Citation: Intensive Care Medicine Experimental 2021 9:10